A list of key references for healthcare professionals.
The following are selected references from pivotal and key Novartis-sponsored or Novartis-funded clinical trials of omalizumab for the treatment of severe allergic asthma.
The links below will take you to non-Novartis websites.
Humbert M et al.
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Allergy 2005;60(3):309–316.
View
Humbert M et al.
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.
Eur Respir J 2018;51(5):1702523.
View
Kulus M et al.
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
Curr Med Res Opin 2010;26(6):1285–1293.
View
